Publications

  1. Finney RE, Czinski S, Fjerstad K, Arteaga GM, Weaver AL, Riggan KA, Allyse MA, Long ME, Torbenson VE, Rivera-Chiauzzi EY. Evaluation of a second victim peer support program on perceptions of second victim experiences and supportive resources in pediatric clinical specialties using the second victim experience and support tool (SVEST). J Pediatr Nurs. 2021 Sep 6; 61:312-317 Epub 2021 Sept 06
    View PubMed
  2. Orellana M, Riggan KA, DSouza K, Stewart EA, Venable S, Balls-Berry JE, Allyse MA. Perceptions of Ethnoracial Factors in the Management and Treatment of Uterine Fibroids. J Racial Ethn Health Disparities. 2021 May 19 [Epub ahead of print]
    View PubMed
  3. Finney RE, Torbenson VE, Riggan KA, Weaver AL, Long ME, Allyse MA, Rivera-Chiauzzi EY. Second victim experiences of nurses in obstetrics and gynaecology: A Second Victim Experience and Support Tool Survey. J Nurs Manag. 2021 May; 29 (4):642-652 Epub 2020 Nov 18
    View PubMed
  4. Rivera-Chiauzzi E, Finney RE, Riggan KA, Weaver AL, Long ME, Torbenson VE, Allyse MA. Understanding the Second Victim Experience Among Multidisciplinary Providers in Obstetrics and Gynecology. J Patient Saf. 2021 Apr 16 [Epub ahead of print]
    View PubMed
  5. Riggan KA, Collura CA, Pittock ST, Ruano R, Whitford KJ, Allyse M. Ethical considerations of maternal-fetal intervention in a twin pregnancy discordant for anomalies. J Matern Fetal Neonatal Med. 2021 Apr; 34 (8):1312-1317 Epub 2019 June 20
    View PubMed
  6. Richardson JP, Riggan KA, Allyse M. The Expert in the Room: Parental Advocacy for Children with Sex Chromosome Aneuploidies. J Dev Behav Pediatr. 2021 Apr 1; 42 (3):213-219
    View PubMed
  7. Torbenson VE, Riggan KA, Weaver AL, Long ME, Finney RE, Allyse MA, Rivera-Chiauzzi E. Second Victim Experience among OBGYN Trainees: What Is Their Desired Form of Support? South Med J. 2021 Apr; 114 (4):218-222
    View PubMed
  8. Orellana M, Valdez-Soto M, Brockman TA, Balls-Berry JE, Zavala Rocha MG, Allyse MA, DSouza KN, Riggan KA, Juhn Y, Patten C. Creating a pediatric advisory board for engaging youth in pediatric health research: A case study. J Clin Transl Sci. 2021 Mar 30; 5 (1):e113
    View PubMed
  9. Riggan KA, Gross B, Close S, Weinberg A, Allyse MA. Prenatal Genetic Diagnosis of a Sex Chromosome Aneuploidy: Parent Experiences. J Genet Couns. 2021 Mar 15 [Epub ahead of print]
    View PubMed
  10. DSouza KN, Orellana M, Riggan KA, Valdez-Soto M, Brockman TA, Zavala Rocha MG, Balls-Berry JE, Juhn Y, Patten CA, Allyse MA. Views and experiences of youth participants in a pediatric advisory board for human subjects research Journal of Clinical and Translational Science. 2021; 5(1):e91.
  11. Riggan KA, Gilbert A, Allyse MA. Acknowledging and Addressing Allostatic Load in Pregnancy Care. J Racial Ethn Health Disparities. 2021 Feb; 8 (1):69-79 Epub 2020 May 07
    View PubMed
  12. Enders FT, Golembiewski EH, Pacheco-Spann LM, Allyse M, Mielke MM, Balls-Berry JE. Building a framework for inclusion in health services research: Development of and pre-implementation faculty and staff attitudes toward the Diversity, Equity, and Inclusion (DEI) plan at Mayo Clinic. J Clin Transl Sci. 2021 Jan 5; 5 (1):e88 Epub 2021 Jan 05
    View PubMed
  13. Riggan KA, Close S, Allyse MA. Family experiences and attitudes about receiving the diagnosis of sex chromosome aneuploidy in a child. Am J Med Genet C Semin Med Genet. 2020 Jun; 184 (2):404-413 Epub 2020 Mar 17
    View PubMed
  14. Gammon BL, Jaramillo C, Riggan KA, Allyse M. Decisional regret in women receiving high risk or inconclusive prenatal cell-free DNA screening results. J Matern Fetal Neonatal Med. 2020 Apr; 33 (8):1412-1418 Epub 2018 Oct 01
    View PubMed
  15. Ainsworth AJ, Allyse M, Khan Z. Fertility Preservation for Transgender Individuals: A Review. Mayo Clin Proc. 2020 Apr; 95 (4):784-792 Epub 2020 Feb 27
    View PubMed
  16. Riggan KA, Khan Z, Langstraat CL, Allyse MA. Provider Knowledge and Support of Uterus Transplantation: Surveying Multidisciplinary Team Members. Mayo Clin Proc Innov Qual Outcomes. 2020 Apr; 4 (2):150-158 Epub 2020 Feb 17
    View PubMed
  17. Meagher KM, Allyse MA, Master Z, Sharp RR. Reexamining the Ethics of Human Germline Editing in the Wake of Scandal. Mayo Clin Proc. 2020 Feb; 95 (2):330-338
    View PubMed
  18. Riggan KA, Nyquist C, Michie M, Allyse MA. Evaluating the Risks and Benefits of Genetic and Pharmacologic Interventions for Down Syndrome: Views of Parents. Am J Intellect Dev Disabil. 2020 Jan; 125 (1):1-13
    View PubMed
  19. Snure Beckman E, Deuitch N, Michie M, Allyse MA, Riggan KA, Ormond KE. Attitudes Toward Hypothetical Uses of Gene-Editing Technologies in Parents of People with Autosomal Aneuploidies. CRISPR J. 2019 Oct; 2 (5):324-330
    View PubMed
  20. Riggan KA, Sharp RR, Allyse M. Where Will We Draw the Line? Public Opinions of Human Gene Editing. Qual Health Res. 2019 Oct; 29 (12):1823-1835 Epub 2019 May 05
    View PubMed
  21. Allyse M, Bombard Y, Isasi R, Michie M, Musunuru K, Ormond KE. What do we do now?: Responding to claims of germline gene editing in humans. Genet Med 2019 Oct; 21 (10):2181-2183 Epub 2019 Mar 27
    View PubMed
  22. Skotko BG, Allyse MA, Bajaj K, Best RG, Klugman S, Leach M, Meredith S, Michie M, Stoll K, Gregg AR. Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. Genet Med. 2019 Oct; 21 (10):2285-2292 Epub 2019 Apr 03
    View PubMed
  23. Ormond KE, Bombard Y, Bonham VL, Hoffman-Andrews L, Howard H, Isasi R, Musunuru K, Riggan KA, Michie M, Allyse M. The clinical application of gene editing: ethical and social issues. Per Med. 2019 Jul; 16 (4):337-350 Epub 2019 July 23
    View PubMed
  24. Riggan KA, Allyse M. 'Compassionate transfer': an alternative option for surplus embryo disposition. Hum Reprod. 2019 May 1; 34 (5):791-794
    View PubMed
  25. Jaramillo C, Nyquist C, Riggan KA, Egginton J, Phelan S, Allyse M. Delivering the Diagnosis of Sex Chromosome Aneuploidy: Experiences and Preferences of Parents and Individuals. Clin Pediatr (Phila). 2019 Mar; 58 (3):336-342 Epub 2018 Dec 05
    View PubMed
  26. Michie M, Allyse M. Gene modification therapies: views of parents of people with Down syndrome. Genet Med. 2019 Feb; 21 (2):487-492 Epub 2018 June 21
    View PubMed
  27. Allyse MA, Wick MJ. Noninvasive Prenatal Genetic Screening Using Cell-free DNA. JAMA. 2018 Aug 14; 320 (6):591-592
    View PubMed
  28. Gammon BL, Otto L, Wick M, Borowski K, Allyse M. Implementing Group Prenatal Counseling for Expanded Noninvasive Screening Options. J Genet Couns. 2018 Aug; 27 (4):894-901 Epub 2017 Dec 15
    View PubMed
  29. Allyse M. CRSPR/CAS 9 and Human Therapeutics. Clin Chem. 2018 Aug 1; 64 (8):1266-1267
    View PubMed
  30. Farrell RM, Allyse MA. Key Ethical Issues in Prenatal Genetics: An Overview. Obstet Gynecol Clin North Am. 2018 Mar; 45 (1):127-141 Epub 2017 Dec 09
    View PubMed
  31. Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing. Mayo Clin Proc. 2018 Jan; 93 (1):113-120
    View PubMed
  32. Allyse M, Wick MJ. What do the new American College of Medical Genetics and Genomics (ACMG) guidelines mean for the provision of non-invasive prenatal genetic screening? J Obstet Gynaecol. 2017 Aug; 37 (6):795-798 Epub 2017 Apr 01
    View PubMed
  33. Stoll KA, Mackison A, Allyse MA, Michie M. Conflicts of interest in genetic counseling: acknowledging and accepting. Genet Med 2017 Aug; 19 (8):864-866 Epub 2017 Jan 26
    View PubMed
  34. Allyse M, Aypar U, Bonhomme N, Darilek S, Dougherty M, Farrell R, Grody W, Highsmith WE, Michie M, Nunes M, Otto L, Pabst R, Palomaki G, Runke C, Sharp RR, Skotko B, Stoll K, Wick M. Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide. J Womens Health (Larchmt). 2017 Jul; 26 (7):755-761 Epub 2017 Apr 07
    View PubMed
  35. Mozersky J, Ravitsky V, Rapp R, Michie M, Chandrasekharan S, Allyse M. Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context. Hastings Cent Rep. 2017 Mar; 47: (2)41-49.
    View PubMed
  36. Parham L, Michie M, Allyse M. Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues Current Genetic Medicine Reports.02/11/2017;
  37. Li G, Chandrasekharan S, Allyse M. "The Top Priority Is a Healthy Baby": Narratives of Health, Disability, and Abortion in Online Pregnancy Forum Discussions in the US and China. J Genet Couns. 2017 Feb; 26 (1):32-39 Epub 2016 June 09
    View PubMed
  38. Tilburt JC, Allyse M, Hafferty FW. The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? AMA J Ethics. 2017 Feb 01; 19 (2):199-206
    View PubMed
  39. Floyd E, Allyse MA, Michie M. Spanish- and English-Speaking Pregnant Women's Views on cfDNA and Other Prenatal Screening: Practical and Ethical Reflections. J Genet Couns. 2016 Oct; 25 (5):965-77 Epub 2016 Jan 07
    View PubMed
  40. Meredith S, Kaposy C, Miller VJ, Allyse M, Chandrasekharan S, Michie M, Prenatal Testing PAG Coalition. Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States. Prenat Diagn. 2016 Aug; 36 (8):714-9 Epub 2016 July 18
    View PubMed
  41. Gammon BL, Kraft SA, Michie M, Allyse M. "I think we've got too many tests!": Prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):334-342
    View PubMed
  42. Michie M, Kraft SA, Minear MA, Ryan RR, Allyse MA. Informed decision-making about prenatal cfDNA screening: An assessment of written materials. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):362-371 Epub 2016 Sept 13
    View PubMed
  43. Li G., Allyse M. Experiences of Mandarin-speaking and English-speaking women of undergoing non-invasive prenatal genetic screening. Ethics, Medicine and Public Health.2016;2:(3):372-82.
  44. Steinbach RJ, Allyse M, Michie M, Liu EY, Cho MK. "This lifetime commitment": Public conceptions of disability and noninvasive prenatal genetic screening. Am J Med Genet A. 2016 Feb; 170A (2):363-374 Epub 2015 Nov 14
    View PubMed
  45. Allyse M, Chandrasekharan S. Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond. Genet Med. 2015 Dec; 17 (12):958-61 Epub 2015 Mar 19
    View PubMed
  46. Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annu Rev Genomics Hum Genet. 2015; 16:369-98.
    View PubMed
  47. Allyse M, Sayres LC, Michie M, Goodspeed T, Cho M. Don't want no risk, don't want no problems: Public understandings of the risks and benefits of novel prenatal technologies in the United States. AJOB Empirical Bioethics.2015;6:(1):5-20.
    View PubMed
  48. Sayres LC, Allyse M, Goodspeed T, Cho MK. Demographic and Experiential Predictors of Public Attitudes towards Cell-Free Fetal DNA Journal of Genetic Counseling.0;23:(6):957-67.
    View PubMed
  49. Chandresekharan S, Minear M, Hung A, Allyse M. Noninvasive prenatal testing goes global. Science Translational Medicine.2014;
  50. Allyse M, Sayres LC, Goodspeed T, Cho MK. Attitudes Towards Non-Invasive Prenatal Testing Among US Adults of Reproductive Age Journal of Perinatology. 2014 March 6.
  51. Allyse M, Minear M, Berson E, Rote M, Sidhar S, Hung A, Chandresekharan S. Non-Invasive Prenatal Testing: A review of international implementation and challenges International Journal of Women's Health. 2014.
  52. Constantine M, Allyse M, Wall M, De Vries R, Rockwood TH. Imperfect Informed Consent in Non-Invasive Prenatal Testing: Lessons from the quad screen. Clinical Ethics.2013;
  53. Berryessa C, Martinex-Martin N, Allyse M. Ethical, Legal and Social Issues Surrounding Research on Genetic Contributions to Anti-Social Behavior Aggression and Violent Behavior.2013;605-610.
  54. Allyse M, Sayres LC, Havard M, Norton ME, Hudgins L, Taylor J, King JS, Cho MK, Greely HT, Magnus D, Ormond KE. Best Practices in the Provision of Non-Invasive Prenatal Diagnosis Prenatal Diagnosis. 2013:656-61.
  55. Allyse M, Michie M. Not-so-incidental-findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing Trends in Biotechnology. 2013:439-41.
  56. Allyse M. 23andMe, We and You: Direct-to-consumer genetics, intellectual property and informed consent Trends in Biotechnology. 2013:68-69.
  57. Goodspeed T, Allyse M, Sayres L, Norton ME, Cho MK. Translating Cell-Free Fetal DNA Trends in Biotechnology.2013;7-9.
  58. Allyse M, Sayres L, Norton M, King JS, Cho MK. Cell-free fetal DNA testing for fetal aneuploidy and beyond: Clinical integration challenges in the United States context Human Reproduction. 2012:3123-3131.
  59. Sayres LC, Allyse M, Goodspeed T, Cho MK. In the public interest? Consequences of broad patenting and restrictive licensing for cell-free fetal DNA testing Science Translational Medicine.2012;
  60. Sayres LC, Allyse M, Cho MK. Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy. Genome Medicine.2012;49.
  61. Tobin SL, Cho MK, Lee SSJ, Magnus D, Allyse M, Ormond KE, Garrison N. Customers or Research Participants? Guidance for Research Practices in Commercialization of Personal Genomics Genetics in Medicine. 2012:833-835.
  62. Allyse M, Karkazis K, Lee SSJ, Tobin SL, Greely HT, Cho MK, Magnus D. Informational Risk, Institutional Review, and Autonomy in the Proposed Changes to the Common Rule IRB: Ethics & Human Research. 2012.
  63. Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation Prenat Diagnosis.2011;1070-6.
  64. Allyse M, Milner LC, Cho MK. Ethics watch: the G.I. genome: ethical implications of genome sequencing in the military Nature Reviews Genetics. 2011; Ethics watch:589.
  65. Allyse M. Embryos, Ethics and Expertise: the emerging model of the scientific research ethics regulator Science and Public Policy. 2010:597-610.